Cargando…
MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
The alterations of MET have been detected in non-small-cell lung cancer (NSCLC). However, survival benefit of MET inhibitors remains controversial. We performed this meta-analysis to evaluate the survival benefit of MET inhibitors combined with an epidermal growth factor receptor tyrosine kinase inh...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650440/ https://www.ncbi.nlm.nih.gov/pubmed/29088885 http://dx.doi.org/10.18632/oncotarget.20824 |
_version_ | 1783272712404205568 |
---|---|
author | Kim, Jung Han Kim, Hyeong Su Kim, Bum Jun |
author_facet | Kim, Jung Han Kim, Hyeong Su Kim, Bum Jun |
author_sort | Kim, Jung Han |
collection | PubMed |
description | The alterations of MET have been detected in non-small-cell lung cancer (NSCLC). However, survival benefit of MET inhibitors remains controversial. We performed this meta-analysis to evaluate the survival benefit of MET inhibitors combined with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) or standard chemotherapy in patients with advanced or metastatic NSCLC. A systematic computerized search of the electronic databases was carried out. From seven studies, 2,577 patients were included in the meta-analysis. Compared with patients in the placebo group, patients who received an additional MET inhibitor did not show significantly improved progression-free survival (hazard ration (HR) = 0.92 [95% confidence interval (CI): 0.79–1.08], P = 0.33) and overall survival (HR = 1.0 [95% CI: 0.90–1.11], P = 0.97). In the subgroup analysis, patients with MET-high NSCLC tended to show longer survival when treated with an additional MET inhibitor than those in the placebo group (HR = 0.76, [95% CI: 0.58–1.01], P = 0.06). In conclusion, this meta-analysis indicates that the addition of a MET inhibitor to an EGFR TKI or chemotherapy has no survival benefit over placebo in patients with advanced or metastatic NSCLC. Although patients with MET-high tumor tended to show better survival, further studies to explore more specific biomarkers are warranted to identify ideal candidates for MET inhibitors in NSCLC. |
format | Online Article Text |
id | pubmed-5650440 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56504402017-10-30 MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review Kim, Jung Han Kim, Hyeong Su Kim, Bum Jun Oncotarget Meta-Analysis The alterations of MET have been detected in non-small-cell lung cancer (NSCLC). However, survival benefit of MET inhibitors remains controversial. We performed this meta-analysis to evaluate the survival benefit of MET inhibitors combined with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) or standard chemotherapy in patients with advanced or metastatic NSCLC. A systematic computerized search of the electronic databases was carried out. From seven studies, 2,577 patients were included in the meta-analysis. Compared with patients in the placebo group, patients who received an additional MET inhibitor did not show significantly improved progression-free survival (hazard ration (HR) = 0.92 [95% confidence interval (CI): 0.79–1.08], P = 0.33) and overall survival (HR = 1.0 [95% CI: 0.90–1.11], P = 0.97). In the subgroup analysis, patients with MET-high NSCLC tended to show longer survival when treated with an additional MET inhibitor than those in the placebo group (HR = 0.76, [95% CI: 0.58–1.01], P = 0.06). In conclusion, this meta-analysis indicates that the addition of a MET inhibitor to an EGFR TKI or chemotherapy has no survival benefit over placebo in patients with advanced or metastatic NSCLC. Although patients with MET-high tumor tended to show better survival, further studies to explore more specific biomarkers are warranted to identify ideal candidates for MET inhibitors in NSCLC. Impact Journals LLC 2017-09-11 /pmc/articles/PMC5650440/ /pubmed/29088885 http://dx.doi.org/10.18632/oncotarget.20824 Text en Copyright: © 2017 Kim et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Meta-Analysis Kim, Jung Han Kim, Hyeong Su Kim, Bum Jun MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review |
title | MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review |
title_full | MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review |
title_fullStr | MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review |
title_full_unstemmed | MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review |
title_short | MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review |
title_sort | met inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review |
topic | Meta-Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650440/ https://www.ncbi.nlm.nih.gov/pubmed/29088885 http://dx.doi.org/10.18632/oncotarget.20824 |
work_keys_str_mv | AT kimjunghan metinhibitorsinadvancednonsmallcelllungcancerametaanalysisandreview AT kimhyeongsu metinhibitorsinadvancednonsmallcelllungcancerametaanalysisandreview AT kimbumjun metinhibitorsinadvancednonsmallcelllungcancerametaanalysisandreview |